Molecular pathways: microRNAs as cancer therapeutics.

Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities. Clin Cancer Res (2015) 1.46

MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin (2014) 1.40

MicroRNAs and DNA damage response: implications for cancer therapy. Cell Cycle (2012) 1.11

Sp1-mediated microRNA-182 expression regulates lung cancer progression. Oncotarget (2014) 1.07

MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro Oncol (2013) 0.99

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol (2014) 0.95

Molecular pathways: microRNAs, cancer cells, and microenvironment. Clin Cancer Res (2014) 0.95

The identification of novel targets of miR-16 and characterization of their biological functions in cancer cells. Mol Cancer (2013) 0.92

Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget (2015) 0.88

Application of concave microwells to pancreatic tumor spheroids enabling anticancer drug evaluation in a clinically relevant drug resistance model. PLoS One (2013) 0.87

MicroRNA Targeting to Modulate Tumor Microenvironment. Front Oncol (2016) 0.86

miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8. Int J Clin Exp Pathol (2014) 0.85

MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma. Oncotarget (2015) 0.85

miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem (2014) 0.84

miR-675-5p enhances tumorigenesis and metastasis of esophageal squamous cell carcinoma by targeting REPS2. Oncotarget (2016) 0.81

A microRNA molecular modeling extension for prediction of colorectal cancer treatment. BMC Cancer (2015) 0.80

MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. Oncotarget (2016) 0.79

Understanding microRNA-mediated gene regulatory networks through mathematical modelling. Nucleic Acids Res (2016) 0.78

Epigenetic mechanisms in penile carcinoma. Int J Mol Sci (2013) 0.77

NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer? J Nanobiotechnology (2016) 0.76

MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways. Sci Rep (2017) 0.75

MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression. J Cancer Res Clin Oncol (2016) 0.75

MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83

Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56

Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29

Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26

5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 11.78

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10

Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30

Modulation of microRNA processing by p53. Nature (2009) 7.88

MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol (2008) 7.27

Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85

The let-7 family of microRNAs. Trends Cell Biol (2008) 6.24

Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07

The miR-34 family in cancer and apoptosis. Cell Death Differ (2009) 5.92

RNAi: nature abhors a double-strand. Curr Opin Genet Dev (2002) 5.74

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res (2007) 5.67

Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80

Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet (2010) 4.27

Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res (2007) 3.89

Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88

DICER1 mutations in familial pleuropulmonary blastoma. Science (2009) 3.82

Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol (2006) 3.71

LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene (2006) 3.49

MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle (2005) 2.99

Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res (2006) 2.83

Regression of murine lung tumors by the let-7 microRNA. Oncogene (2009) 2.83

A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell (2010) 2.78

Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75

Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev (2010) 2.37

Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21

Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96

A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta (1999) 1.92

Isolation of transforming sequences of two human lung carcinomas: structural and functional analysis of the activated c-K-ras oncogenes. Proc Natl Acad Sci U S A (1984) 1.89

A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol (2008) 1.80

Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther (2011) 1.76

MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer (2010) 1.48

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer (2010) 1.46

Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis (2010) 1.42

ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res (2011) 1.37

Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs (2001) 1.29

A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res (2009) 1.23

The expanding role of fluoroquinolones. Am J Med (2002) 1.13

Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer (2002) 1.12

Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res (2000) 1.01

The chemical and biological aspects of fluoroquinolones: reality and dreams. Curr Pharm Des (2001) 0.97

The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer (1997) 0.94

Activation of the c-K-ras oncogene in a human pancreas carcinoma. Biochem Biophys Res Commun (1985) 0.89

The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16

Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51

BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91

Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol (2008) 5.83

TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet (2005) 5.53

Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem (2007) 5.37

Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med (2010) 4.88

Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65

Origin and function of myofibroblasts in kidney fibrosis. Nat Med (2013) 4.55

Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20

Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01

Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res (2007) 3.86

Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell (2003) 3.68

eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell (2012) 3.63

Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med (2010) 3.60

Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem (2003) 3.36

The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl) (2004) 3.32

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19

Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int (2002) 3.16

Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A (2006) 3.03

Endogenous inhibitors of angiogenesis. Cancer Res (2005) 2.88

Loss of β1-integrin from urothelium results in overactive bladder and incontinence in mice: a mechanosensory rather than structural phenotype. FASEB J (2013) 2.86

Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem (2007) 2.67

Cancer without disease. Nature (2004) 2.65

Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med (2013) 2.55

Biomolecular characterization and protein sequences of the Campanian hadrosaur B. canadensis. Science (2009) 2.48

Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med (2012) 2.44

Structure and function of basement membranes. Exp Biol Med (Maywood) (2007) 2.29

Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A (2003) 2.28

Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (2002) 2.28

TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol (2012) 2.24

Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21

Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol (2003) 2.20

The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol (2010) 2.18

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17

Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem (2004) 2.13

Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) (2013) 2.12

Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature (2008) 2.09

The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol (2010) 2.03

BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J (2006) 2.02

Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology (2003) 1.97

Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes (2007) 1.94

Determinants of vascular permeability in the kidney glomerulus. J Biol Chem (2002) 1.93

Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem (2014) 1.92

Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol (2009) 1.83

NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest (2002) 1.81

Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol (2007) 1.79

Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem (2005) 1.79

Origins of cardiac fibroblasts. Circ Res (2010) 1.76

Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol (2012) 1.70

Mice deficient in alpha-actinin-4 have severe glomerular disease. J Clin Invest (2003) 1.69

Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest (2005) 1.66

Transforming growth factor-β2 promotes Snail-mediated endothelial-mesenchymal transition through convergence of Smad-dependent and Smad-independent signalling. Biochem J (2011) 1.65

Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl (2010) 1.64

Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol (2002) 1.63

VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A (2011) 1.60

Integrin beta1-mediated matrix assembly and signaling are critical for the normal development and function of the kidney glomerulus. Dev Biol (2007) 1.60

Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem (2010) 1.58

Alpha-actinin-4 is required for normal podocyte adhesion. J Biol Chem (2006) 1.58

Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med (2006) 1.54

Type IV collagen-derived angiogenesis inhibitors. Microvasc Res (2007) 1.51

Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A (2005) 1.51

Human antiglomerular basement membrane autoantibody disease in XenoMouse II. Kidney Int (2002) 1.50

Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis. Front Biosci (2008) 1.44

Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res (2004) 1.42

Tumor microenvironment and angiogenesis. Front Biosci (2008) 1.38

Epithelial-mesenchymal transition. Cancer Res (2008) 1.37

Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant (2007) 1.37

Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Semin Cancer Biol (2012) 1.35

VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res (2009) 1.32

Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev (2009) 1.32

Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol (2009) 1.29

Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res (2003) 1.29

A role for nephrin, a renal protein, in vertebrate skeletal muscle cell fusion. Proc Natl Acad Sci U S A (2009) 1.26

Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int (2004) 1.26

The importance of cell-mediated immunity in the course and severity of autoimmune anti-glomerular basement membrane disease in mice. FASEB J (2003) 1.25

Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int (2002) 1.24

Beta1 integrin expression on endothelial cells is required for angiogenesis but not for vasculogenesis. Dev Dyn (2008) 1.24

Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun (2005) 1.22

The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med (2012) 1.21

Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab Invest (2008) 1.19

Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation (2010) 1.18

Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res (2006) 1.17

Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr Mol Med (2005) 1.17

The biology of preeclampsia. Kidney Int (2009) 1.16

Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int (2003) 1.15

Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem (2011) 1.14

The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. Genes Cancer (2011) 1.14

Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A (2011) 1.13

Animal models of renal fibrosis. Methods Mol Med (2005) 1.11

The role of type IV collagen and basement membranes in cancer progression and metastasis. Am J Pathol (2006) 1.11

Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends Endocrinol Metab (2010) 1.10

Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol (2008) 1.08

Experimental strategies to reverse chronic renal disease. Blood Purif (2004) 1.08

A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development. J Am Soc Nephrol (2002) 1.06

Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proc Natl Acad Sci U S A (2008) 1.05

Basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis inhibitors and suppress tumor growth. Exp Biol Med (Maywood) (2008) 1.04

The biology and function of exosomes in cancer. J Clin Invest (2016) 1.04

Transcriptional regulation of epithelial-mesenchymal transition. J Clin Invest (2007) 1.03

Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol (2010) 1.03